Compare Costco Wholesale Corporation (COST) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Crispr Therapeutics AG — how do they compare? Costco Wholesale Corporation trades at $921.82 (market cap $408.78B), while Crispr Therapeutics AG trades at $50.93 (market cap $4.97B). The key difference: Costco Wholesale Corporation is far larger — about 82.2× Crispr Therapeutics AG's market cap, and Costco Wholesale Corporation pays a 0.64% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| COST | CRSP | |
|---|---|---|
Market Cap | $408.78B | $4.97B |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $76.78 |
52-Week Low | $849.63 | $44.34 |
Enterprise Value | $396.92B | $3.32B |
Dividend Yield | 0.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COST trades at $926.43, up 1.11% over 24h, with a bearish technical signal but strong fundamentals. Revenue grew to $275.24B in 2025, with net income of $8.10B, though Q1 2026 EPS missed expectations. The stock's valuation is elevated with a P/E of 46.37, while analyst consensus remains bullish with a $1,120 price target. Recent news highlights membership fee hikes and March sales growth of 11.3% year-over-year, indicating resilient consumer demand.
Outlook is mixed: robust membership model and sales trends support growth, but high valuation and technical bearishness pose near-term risks. Investors should weigh strong cash flow and analyst optimism against potential pullbacks from current levels. Key risks include competitive pressures and macroeconomic sensitivity, though institutional buying signals confidence.
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
